EcoDrugPlus

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSCHYG00000011100
Gene Symbol: PSMB7
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCHYG00000004467
Gene Symbol: PSMB8
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSCHYG00000008396
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSCHYG00000018422
Gene Symbol: PSMC1
1 Cross references
315 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSCHYG00000025139
Gene Symbol: PSMC2
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSCHYG00000003185
Gene Symbol: PSMC3
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSCHYG00000027145
Gene Symbol: PSMC4
1 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSCHYG00000011842
Gene Symbol: PSMC5
1 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSCHYG00000010484
Gene Symbol: PSMD1
1 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSCHYG00000005685
Gene Symbol: PSMD11
1 Cross references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSCHYG00000017208
Gene Symbol: PSMD12
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSCHYG00000006127
Gene Symbol: PSMD13
1 Cross references
220 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).